NASDAQ:PSNL - Personalis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.29
  • Forecasted Upside: 437.29 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$4.52
▼ -0.44 (-8.87%)

This chart shows the closing price for PSNL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Personalis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSNL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSNL

Analyst Price Target is $24.29
▲ +437.29% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Personalis in the last 3 months. The average price target is $24.29, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 437.29% upside from the last price of $4.52.

This chart shows the closing price for PSNL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Personalis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/13/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/11/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/9/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/10/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2022HC WainwrightLower Price TargetBuy$30.00 ➝ $26.00N/A
5/5/2022CitigroupLower Price Target$18.00 ➝ $14.00High
5/5/2022HC WainwrightLower Price Target$38.00 ➝ $30.00High
2/25/2022OppenheimerLower Price TargetOutperform$30.00 ➝ $24.00Low
2/25/2022HC WainwrightLower Price TargetBuy$50.00 ➝ $38.00High
2/25/2022CitigroupLower Price TargetBuy$30.00 ➝ $18.00High
1/7/2022BTIG ResearchReiterated RatingBuy$30.00High
1/7/2022Bank of AmericaUpgradeNeutral ➝ Buy$27.00 ➝ $23.00High
11/5/2021BTIG ResearchReiterated RatingBuy$29.00Low
11/5/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$32.00 ➝ $25.00High
11/3/2021Needham & Company LLCDowngradeBuy ➝ HoldLow
9/23/2021HC WainwrightReiterated RatingBuy$50.00Low
9/21/2021BTIG ResearchLower Price TargetBuy$35.00 ➝ $30.00High
9/20/2021Needham & Company LLCLower Price TargetBuy$33.00 ➝ $28.00Medium
8/5/2021CitigroupLower Price TargetBuy$37.00 ➝ $30.00High
5/13/2021Truist FinancialLower Price TargetBuy ➝ Buy$37.00 ➝ $29.00High
5/7/2021Morgan StanleyLower Price TargetOverweight$38.00 ➝ $35.00High
5/6/2021Needham & Company LLCLower Price TargetBuy$38.00 ➝ $33.00High
5/6/2021OppenheimerUpgradeMarket Perform ➝ Outperform$28.00High
4/14/2021OppenheimerReiterated RatingHoldMedium
3/1/2021Morgan StanleyBoost Price TargetOverweight$27.00 ➝ $38.00Low
2/26/2021Needham & Company LLCReiterated RatingBuy$38.00High
1/27/2021Truist FinancialInitiated CoverageBuy$50.00High
1/13/2021HC WainwrightBoost Price TargetBuy$30.00 ➝ $50.00Low
1/12/2021OppenheimerReiterated RatingHoldHigh
1/4/2021Bank of AmericaDowngradeBuy ➝ Neutral$40.00N/A
12/16/2020Smith Barney CitigroupBoost Price Target$35.00 ➝ $45.00Low
11/12/2020Needham & Company LLCBoost Price TargetIn-Line ➝ Buy$25.00 ➝ $32.00Low
11/9/2020Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $27.00High
11/6/2020OppenheimerReiterated RatingOutperform ➝ Market PerformHigh
10/19/2020Smith Barney CitigroupInitiated CoverageBuy$35.00Medium
10/7/2020BTIG ResearchInitiated CoverageBuy$35.00Medium
9/23/2020HC WainwrightReiterated RatingBuy$30.00High
8/27/2020HC WainwrightInitiated CoverageBuy$30.00Medium
8/17/2020Needham & Company LLCInitiated CoverageBuy$25.00Low
8/7/2020Morgan StanleyBoost Price TargetOverweight$14.00 ➝ $25.00Low
6/24/2020OppenheimerInitiated CoverageBuy$24.00High
5/8/2020Morgan StanleyBoost Price TargetOverweight$13.00 ➝ $14.00High
5/7/2020OppenheimerInitiated CoverageBuy$24.00Medium
4/21/2020OppenheimerInitiated CoverageBuy$24.00Medium
3/26/2020Morgan StanleyLower Price TargetOverweight$16.00 ➝ $13.00Low
11/14/2019OppenheimerLower Price TargetOutperform$29.00 ➝ $26.00High
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$22.00High
7/15/2019CIBCInitiated CoverageOutperform ➝ Outperform$29.00Medium
7/15/2019CowenInitiated CoverageOutperform ➝ OutperformHigh
7/15/2019OppenheimerInitiated CoverageOutperform$29.00 ➝ $29.00High
7/15/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$28.00High
7/15/2019Bank of AmericaInitiated CoverageNeutral ➝ Neutral$27.00High
(Data available from 8/9/2017 forward)

News Sentiment Rating

-0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/9/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
3/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/10/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
5/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/9/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/9/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 7 very negative mentions
8/8/2022

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 7 very negative mentions

Recent Stories by Sentiment

Personalis logo
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $4.52
Low: $4.46
High: $5.02

50 Day Range

MA: $3.85
Low: $3.27
High: $4.96

52 Week Range

Now: $4.52
Low: $3.13
High: $23.04

Volume

676,120 shs

Average Volume

478,089 shs

Market Capitalization

$207.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.65

Frequently Asked Questions

What sell-side analysts currently cover shares of Personalis?

The following Wall Street sell-side analysts have issued reports on Personalis in the last year: Bank of America Co., BTIG Research, Citigroup Inc., HC Wainwright, Morgan Stanley, Needham & Company LLC, and Oppenheimer Holdings Inc..
View the latest analyst ratings for PSNL.

What is the current price target for Personalis?

7 Wall Street analysts have set twelve-month price targets for Personalis in the last year. Their average twelve-month price target is $24.29, suggesting a possible upside of 437.3%. BTIG Research has the highest price target set, predicting PSNL will reach $30.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $14.00 for Personalis in the next year.
View the latest price targets for PSNL.

What is the current consensus analyst rating for Personalis?

Personalis currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSNL will outperform the market and that investors should add to their positions of Personalis.
View the latest ratings for PSNL.

What other companies compete with Personalis?

Other companies that are similar to Personalis include DermTech, Celcuity, Biora Therapeutics, Progenity and Exagen. Learn More about companies similar to Personalis.

How do I contact Personalis' investor relations team?

Personalis' physical mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company's listed phone number is (650) 752-1300 and its investor relations email address is [email protected] The official website for Personalis is www.personalis.com. Learn More about contacing Personalis investor relations.